What Is Urolithin A and How Does It Trigger Mitophagy?
Urolithin A doesn't exist in any food you can buy. It's a metabolite — a compound your gut bacteria manufacture after you eat foods rich in ellagitannins and ellagic acid, primarily pomegranates, but also walnuts, raspberries, and strawberries in smaller amounts. Your gut microbiome converts these plant polyphenols into urolithin A through a multi-step bacterial fermentation process.
This is why urolithin A is often classified as a postbiotic rather than a plant compound: the biological activity comes from what your bacteria make, not what you directly ingest. And this creates a well-documented problem — research has found that only a subset of people, commonly cited around 40% in published cohorts, carry the specific gut flora capable of producing meaningful circulating levels of urolithin A after eating pomegranate. Everyone else is what researchers call a "low producer" or "non-producer," regardless of how much pomegranate they eat.
The Mitophagy Mechanism
The foundational discovery came from Ryu et al., published in Nature Medicine in 2016 ("Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents"). The researchers identified urolithin A as a first-in-class natural compound that induces mitophagy — the selective autophagic clearance of damaged or dysfunctional mitochondria — both in cell culture and after oral consumption in living organisms.
Mitochondria are not static. Like any cellular machinery, they accumulate damage over time from oxidative stress and metabolic wear. Under normal conditions, a healthy cell identifies these damaged mitochondria and tags them for removal via mitophagy, then replaces them with new, functional mitochondria through mitochondrial biogenesis. This quality-control cycle declines with age — damaged mitochondria are cleared more slowly and accumulate, which is linked to the reduced energy production and muscle decline associated with aging.
In the 2016 study, urolithin A prevented the accumulation of dysfunctional mitochondria with age in C. elegans, extended lifespan, and preserved normal activity during aging including mobility and pharyngeal pumping. In rodent models, urolithin A improved exercise capacity in two different models of age-related muscle decline, as well as in young rats — suggesting the effect isn't limited to reversing existing dysfunction but may also support muscle performance more broadly.
The Human Evidence: JAMA Network Open, 2022
Preclinical mitophagy data is common in the longevity-supplement space; what makes urolithin A unusual is that it has actual randomized human trial data behind a specific, measurable outcome.
Liu, D'Amico, Shankland, Bhayana, Garcia, Aebischer, et al. published "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial" in JAMA Network Open (2022;5(1):e2144279). The trial enrolled adults aged 65-90 and randomized them to 1,000 mg/day of urolithin A or placebo for four months.
The supplemented group showed significantly improved muscle endurance in both leg and hand skeletal muscles compared to placebo. On the 6-minute walk test — a standard clinical measure of functional exercise capacity — the urolithin A group improved by an average of 60.8 meters from baseline, compared to 42.5 meters in the placebo group. The trial also reported improvements in biomarkers of mitochondrial health.
A separate 8-week randomized, double-blind, placebo-controlled study in resistance-trained male athletes examined urolithin A's effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism, extending the evidence base beyond the older-adult population into a younger, trained cohort. As with most nutraceutical research, sample sizes across these trials remain modest, and the field would benefit from larger, independently funded replications.
Why Food Alone Won't Get You There
Because urolithin A production depends on gut bacterial composition, eating pomegranates — even a lot of them — does not reliably deliver meaningful urolithin A levels. Studies using pomegranate extract or juice have found highly variable urolithin A production between individuals, with some participants producing almost none regardless of dose. This inter-individual variability is the core rationale for direct urolithin A supplementation rather than relying on precursor-rich foods.
| Source | Delivers Urolithin A Directly? | Reliability |
|---|---|---|
| Pomegranates (whole fruit or juice) | No — provides precursor ellagitannins only | Low; depends on individual gut flora |
| Walnuts | No — smaller precursor amounts than pomegranate | Low |
| Direct urolithin A supplement | Yes — bypasses the gut-conversion step entirely | High; consistent dosing regardless of microbiome |
Dosing Protocols
The only dose with published randomized human outcome data behind it is 1,000 mg/day, taken for four months in the JAMA Network Open trial. Most commercial urolithin A supplements are formulated at 500 mg/day for general-use maintenance, with some brands offering a 1,000 mg option specifically positioned to match the studied protocol.
- General maintenance: 500 mg/day, taken with a meal
- Trial-matched protocol: 1,000 mg/day, consistent daily use for at least 4 months before expecting measurable functional change
The StackProtocol Mitochondrial Health Stack
Mitophagy + Biogenesis Stack
Urolithin A clears damaged mitochondria; pairing it with compounds that support new mitochondrial growth targets both halves of the quality-control cycle
Evidence Summary
| Study / Source | Finding | Evidence Level |
|---|---|---|
| Ryu et al. 2016 Nature Medicine 22(8):879-888 |
First identification of urolithin A as a mitophagy inducer; extended lifespan and preserved mobility in C. elegans; improved exercise capacity in rodent models of age-related muscle decline | Preclinical |
| Liu, D'Amico, Shankland et al. 2022 JAMA Network Open 5(1):e2144279 |
Randomized, placebo-controlled trial in adults 65-90; 1,000 mg/day for 4 months improved 6-minute walk distance (+60.8m vs +42.5m placebo) and skeletal muscle endurance | Human RCT (industry-funded, N in the low dozens) |